anti-BCMA/CD3 bispecific antibody
IIT2025139
Phase 2 small_molecule active
Quick answer
anti-BCMA/CD3 bispecific antibody for Multiple Myeloma is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active